Live Breaking News & Updates on Ionis Pharmaceuticals Price Performance

Stay updated with breaking news from Ionis pharmaceuticals price performance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Baillie Gifford & Co. Has $13.55 Million Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Baillie Gifford & Co. Has $13.55 Million Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.

United States , C Frank Bennett , Raymond James , Ionis Pharmaceuticals Price Performance , Ionis Pharmaceuticals , China Universal Asset Management Co , Whittier Trust Co , Ionis Pharmaceuticals Profile , Securities Exchange Commission , Ionis Pharmaceuticals Inc , Needham Company , News Ratings For Ionis Pharmaceuticals Daily , Quarter For Ionis Pharmaceuticals , Baillie Gifford Co , Morgan Stanley , Almanack Investment Partners , Royal Bank , Holdings Channel , Nevada Inc , Baillie Gifford , Free Report , Investment Partners , Financial Advisors , China Universal Asset Management , Universal Asset Management , Get Free Report ,

Ionis Pharmaceuticals (NASDAQ:IONS) Posts Quarterly Earnings Results, Beats Expectations By $1.54 EPS

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.60 EPS for the quarter, topping the consensus estimate of ($0.94) by $1.54, reports. The business had revenue of $188.00 million during the quarter, compared to analysts’ expectations of $136.84 million. Ionis Pharmaceuticals had a negative net margin […] ....

United States , Allenem Diaz , Norges Bank , Securities Exchange Commission , Needham Company , Ionis Pharmaceuticals , News Ratings For Ionis Pharmaceuticals Daily , Institutional Investors Weigh In On Ionis Pharmaceuticals , Earnings History For Ionis Pharmaceuticals , Ionis Pharmaceuticals Price Performance , Ionis Pharmaceuticals Inc , Tweedy Browne Co , Get Free Report , Director Allene , Exchange Commission , World Investors , Pictet Asset Management , Asset Management , Ionis Pharmaceuticals Daily , Nasdaq Ions ,

AtonRa Partners Cuts Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

AtonRa Partners lowered its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 11.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,344 shares of the company’s stock after selling 1,531 shares during the quarter. AtonRa Partners’ holdings in […] ....

United States , Banque Cantonale Vaudoise , Quarter For Ionis Pharmaceuticals , Morgan Stanley , Ionis Pharmaceuticals , Almanack Investment Partners , Nevada Inc , Ionis Pharmaceuticals Company Profile , Ionis Pharmaceuticals Inc , News Ratings For Ionis Pharmaceuticals Daily , Whittier Trust Co , England Capital Financial Advisors , Ionis Pharmaceuticals Price Performance , Securities Exchange Commission , Atonra Partners , Free Report , Investment Partners , Cantonale Vaudoise , New England Capital Financial Advisors , Exchange Commission , Director Joseph Klein , Get Free Report , Ionis Pharmaceuticals Daily , Nasdaq Ions , Sec Filings , Hedge Fund Holdings ,

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives $46.64 Average Price Target from Brokerages

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) has been given a consensus recommendation of “Hold” by the fourteen ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. […] ....

United States , Patrickr Oneil , News Ratings For Ionis Pharmaceuticals Daily , Securities Exchange Commission , Raymond James Financial Services Advisors Inc , Institutional Trading Of Ionis Pharmaceuticals , Ionis Pharmaceuticals , Metlife Investment Management , Analyst Recommendations For Ionis Pharmaceuticals , Royal Bank , Morgan Stanley , Ionis Pharmaceuticals Inc , Us Bancorp , Ionis Pharmaceuticals Price Performance , American Century Companies Inc , Financial Services Group Inc , Get Rating , Marketbeat Ratings , Exchange Commission , James Financial Services Advisors , Century Companies , Services Group , Ionis Core , Ionis Pharmaceuticals Daily , Nasdaq Ions ,

126,300 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Purchased by M28 Capital Management LP

M28 Capital Management LP bought a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 126,300 shares of the company’s stock, valued at approximately $4,770,000. Ionis Pharmaceuticals makes up 4.5% of M28 Capital Management LP’s holdings, making the stock its 6th largest […] ....

United States , Patrickr Oneil , Delphia United States Inc , News Ratings For Ionis Pharmaceuticals Daily , Needham Company , Profund Advisors , Quarter For Ionis Pharmaceuticals , Ionis Pharmaceuticals Price Performance , Lincoln National Corp , Commerce Bank , Ionis Pharmaceuticals , Ionis Pharmaceuticals Inc , Get Rating , Financial Advisors , National Corp , Ionis Core , Visit Holdingschannel , Ionis Pharmaceuticals Daily , Nasdaq Ions , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,